4967 小林製薬

累計 / 通期：4Q / 3Q / 2Q / 1Q

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2024/12	4Q	165,600	24,860	15.0%	26,861	16.2%	10,067	6.1%	135.42	-4.5%	-3.6%	-1.7%	-50.5%
2023/12	4Q	173,455	25,780	14.9%	27,330	15.8%	20,338	11.7%	268.16	4.3%	-3.3%	-3.4%	1.6%
2022/12	4Q	166,258	26,669	16.0%	28,281	17.0%	20,022	12.0%	259.63	7.1%	2.3%	0.9%	1.6%
2021/12	4Q	155,252	26,065	16.8%	28,015	18.0%	19,715	12.7%	252.36	3.1%	0.5%	1.0%	2.7%
2020/12	4Q	150,514	25,943	17.2%	27,726	18.4%	19,205	12.8%	245.71	-10.4%	-1.6%	-0.4%	0.3%
2019/12	4Q	168,052	26,355	15.7%	27,851	16.6%	19,139	11.4%	244.08	0.3%	0.3%	1.7%	6.2%
2018/12	4Q	167,479	26,289	15.7%	27,374	16.3%	18,023	10.8%	228.05	-	-	-	-

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2024/12	4Q	165,600	24,860	15.0%	26,861	16.2%	10,067	6.1%	135.42	-4.5%	-3.6%	-1.7%	-50.5%
2023/12	4Q	173,455	25,780	14.9%	27,330	15.8%	20,338	11.7%	268.16	4.3%	-3.3%	-3.4%	1.6%
2022/12	4Q	166,258	26,669	16.0%	28,281	17.0%	20,022	12.0%	259.63	7.1%	2.3%	0.9%	1.6%
2021/12	4Q	155,252	26,065	16.8%	28,015	18.0%	19,715	12.7%	252.36	3.1%	0.5%	1.0%	2.7%
2020/12	4Q	150,514	25,943	17.2%	27,726	18.4%	19,205	12.8%	245.71	-10.4%	-1.6%	-0.4%	0.3%
2019/12	4Q	168,052	26,355	15.7%	27,851	16.6%	19,139	11.4%	244.08	0.3%	0.3%	1.7%	6.2%
2018/12	4Q	167,479	26,289	15.7%	27,374	16.3%	18,023	10.8%	228.05	-	-	-	-